Amgen Inc.

AMGN

$167.60B

Large Cap

NASDAQBiological Products, (No Diagnostic Substances)Biotechnology🇺🇸North AmericaTHOUSAND OAKS28.0K employees

Amgen Inc. is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. The company is ranked 18th on the list of largest biomedical companies by revenue. The name "AMGen" is a portmanteau of the company's original name, Applied Molecular Genetics.

Website

Drugs in Pipeline

197

Phase 3 Programs

117

Upcoming Catalysts

Next Catalyst

Feb 28, 2026

20d

Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply

Market Overview

Stock performance and market intelligence

Catalyst Timeline

18 upcoming, 1 past

Phase 2Next

sotorasib Phase 2 Results Expected

Feb 28, 2026Lumakras713

Primary completion for sotorasib trial (NCT03600883) in KRAS p.G12C Mutant Advanced Solid Tumors

Source

Phase 2

HZN-1116 Phase 2 Results Expected

Mar 19, 2026HZN-1116209

Primary completion for HZN-1116 trial (NCT06312020) in Sjogren's Syndrome

Source

Phase 2

AMG 193 Phase 2 Results Expected

Apr 1, 2026AMG 19353

Primary completion for AMG 193 trial (NCT05975073) in MTAP-null Non-Small-Cell Lung Cancer

Source

Phase 2

IDE397 Phase 2 Results Expected

Apr 1, 2026IDE39753

Primary completion for IDE397 trial (NCT05975073) in MTAP-null Non-Small-Cell Lung Cancer

Source

⭐Phase 3

Romiplostim Phase 3 Results Expected

May 20, 2026Romiplostim162

Primary completion for Romiplostim trial (NCT03937154) in Chemotherapy-induced Thrombocytopenia

Source

⭐Phase 3

Dazodalibep Phase 3 Results Expected

Jun 24, 2026Dazodalibep651

Primary completion for Dazodalibep trial (NCT06104124) in Sjogren's Syndrome

Source

⭐Phase 3

Pembrolizumab Phase 3 Results Expected

Jun 30, 2026Pembrolizumab750

Primary completion for Pembrolizumab trial (NCT05920356) in Non-Small Cell Lung Cancer (NSCLC)

Source

⭐Phase 3

Sotorasib Phase 3 Results Expected

Jun 30, 2026Sotorasib750

Primary completion for Sotorasib trial (NCT05920356) in Non-Small Cell Lung Cancer (NSCLC)

Source

Phase 2

Docetaxel Phase 2 Results Expected

Jul 2, 2026Docetaxel649

Primary completion for Docetaxel trial (NCT05094336) in Advanced MTAP-null Solid Tumors

Source

Phase 2

AMG 193 Phase 2 Results Expected

Jul 2, 2026AMG 193649

Primary completion for AMG 193 trial (NCT05094336) in Advanced MTAP-null Solid Tumors

Source

⭐Phase 3

Dazodalibep Phase 3 Results Expected

Sep 2, 2026Dazodalibep435

Primary completion for Dazodalibep trial (NCT06245408) in Sjögren's Syndrome (SS)

Source

Phase 2

Rocatinlimab Phase 2 Results Expected

Oct 19, 2026Rocatinlimab317

Primary completion for Rocatinlimab trial (NCT06376045) in Asthma

Source

⭐Phase 3

Dazodalibep Phase 3 Results Expected

Oct 22, 2026Dazodalibep434

Primary completion for Dazodalibep trial (NCT06245408) in Sjögren's Syndrome (SS)

Source

⭐Phase 3

Rocatinlimab Phase 3 Results Expected

Oct 30, 2026Rocatinlimab469

Primary completion for Rocatinlimab trial (NCT06527404) in Prurigo Nodularis

Source

⭐Phase 3

ABP 234 Phase 3 Results Expected

Dec 14, 2026ABP 234154

Primary completion for ABP 234 trial (NCT06430866) in Early-stage Non-squamous Non-small Cell Lung Cancer (NSCLC)

Source

Phase 2

Tarlatamab Phase 2 Results Expected

Dec 30, 2026Tarlatamab222

Primary completion for Tarlatamab trial (NCT05060016) in Relapsed/Refractory Small Cell Lung Cancer

Source

⭐Phase 3

Ocrelizumab (US) Phase 3 Results Expected

Jan 15, 2027Ocrelizumab (US)444

Primary completion for Ocrelizumab (US) trial (NCT06700343) in Relapsing-remitting Multiple Sclerosis (RRMS)

Source

⭐Phase 3

Maridebart cafraglutide Phase 3 Results Expected

Jan 21, 2027Maridebart cafraglutide3,853

Primary completion for Maridebart cafraglutide trial (NCT06858878) in Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight

Source

AI Predictions & Institutional Flow

Machine learning insights and smart money movement

FDA Submissions

Pending NDA/BLA submissions with predicted PDUFA dates

Drug Pipeline

Clinical development programs and drug candidates

Drug Pipeline

Lumakras

Sotorasib

Approved

KRAS G12C NSCLC

Fast TrackBreakthrough

ABP 980

Drug Name	Phase	Indication	Designations
Lumakras Sotorasib	Approved	KRAS G12C NSCLC	Fast TrackBreakthrough
ABP 980	Phase 3	Breast Cancer	-
Ustekinumab	Phase 3	Psoriasis	-
Rosuvastatin	Phase 3	Hyperlipidemia	-
Trifluridine and Tipiracil	Phase 3	Colorectal Cancer (CRC)	-
Apremilast (CC-10004)	Phase 3	Behcet Syndrome	-
Rocatinlimab	Phase 3	Asthma	-
Carboplatin	Phase 3	Non-small Cell Lung Cancer Metastatic	-
Vincrisitne	Phase 3	Leukemia, Acute Lymphoblastic	-
Lanadelumab	Phase 3	COVID-19	-
Topical Therapy	Phase 3	Plaque Psoriasis	-
Lenalidomide	Phase 3	Relapsed Multiple Myeloma	-
MP-376 (Levofloxacin Solution for Inhalation)	Phase 3	Cystic Fibrosis	-
FOLFOX regimen	Phase 3	Metastatic Colorectal Cancer	-
RP103	Phase 3	Cystinosis	-
Blinatumomab	Phase 3	Acute Lymphoblastic Leukemia	-
Adalimumab	Phase 3	Plaque Psoriasis	-
AMG 073	Phase 3	Secondary Hyperparathyroidism	-
Aranesp®	Phase 3	Kidney Disease	-
rHuEPO	Phase 3	Cancer	-
Apremilast 20mg	Phase 3	Psoriatic Arthritis	-
Evolocumab AMD	Phase 3	Primary Hypercholesterolemia	-
De Novo Administration of Darbepoetin Alfa	Phase 3	Chronic Kidney Disease	-
Apremilast 30mg	Phase 3	Psoriatic Arthritis	-
Background Statin Therapy	Phase 3	Dyslipidemia	-
ABP 938	Phase 3	Neovascular (Wet) Age-related Macular Degeneration (AMD)	-
darbepoetin alfa	Phase 3	Anemia	-
Cystagon®	Phase 3	Cystinosis	-
60 mg denosumab	Phase 3	Low Bone Mass	-
Chemotherapy	Phase 3	Gastric Cancer	-
Zoledronic Acid	Phase 3	Bone Metastases	-
Best Supportive Care	Phase 3	Multiple Myeloma	-
Denosumab	Phase 3	Osteoporosis	-
mFOLFOX6	Phase 3	Gastric Cancer	-
Aflibercept	Phase 3	Chorioretinal Vascular Disease	-
Oxaliplatin Based Chemotherapy	Phase 3	Colorectal Cancer	-
Apremilast 30 mg	Phase 3	Psoriatic Arthritis	-
Romosozumab 90 mg/mL	Phase 3	Postmenopausal Osteoporosis	-
Topical treatments or phototherapy	Phase 3	Plaque Psoriasis	-
Standard Chemotherapy	Phase 3	Cancer	-
Recombinant Human Keratinocyte Growth Factor	Phase 3	Stomatitis	-
etanercept pre-filled syringe subcutaneous injection	Phase 3	Rheumatoid Arthritis	-
Anakinra (Kineret®)	Phase 3	Rheumatoid Arthritis	-
Atorvastatin	Phase 3	Diabetes, Hyperlipidemia, Mixed Dyslipidemia	-
AMG 162 / Denosumab	Phase 3	Breast Cancer	-
Teprotumumab	Phase 3	Thyroid Eye Disease	-
1=Etanercept	Phase 3	Psoriasis	-
FOLFIRI	Phase 3	Metastatic Colorectal Cancer	-
Non-steroidal aromatase inhibitor therapy	Phase 3	Breast Cancer	-
Ibuprofen/famotidine	Phase 3	Ulcer	-
Statin therapy	Phase 3	Coronary Artery Disease (CAD)	-
interferon γ-1b	Phase 3	Friedreich's Ataxia	-
Ocrelizumab (US)	Phase 3	Relapsing-remitting Multiple Sclerosis (RRMS)	-
pegfilgrastim	Phase 3	Breast Cancer	-
Ibandronate	Phase 3	Postmenopausal Osteoporosis	-
ABP 710	Phase 3	Arthritis, Rheumatoid	-
Sotorasib	Phase 3	Non-small Cell Lung Cancer	-
Inebilizumab	Phase 3	IgG4 Related Disease	-
Darbepoetin alfa - 2.25 mcg/kg	Phase 3	Anemia	-
Xaluritamig	Phase 3	Metastatic Castration-resistant Prostate Cancer	-
ABP 234	Phase 3	Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer	-
Pembrolizumab	Phase 3	Melanoma	-
Ezetimibe	Phase 3	Hyperlipidemia	-
ABP 501	Phase 3	Arthritis, Rheumatoid	-
Dazodalibep	Phase 3	Sjögren's Syndrome (SS)	-
Topical agents	Phase 3	Psoriasis	-
Aranesp® (darbepoetin alfa)	Phase 3	Kidney Disease	-
AMG 162	Phase 3	Postmenopausal Osteoporosis	-
Cinacalcet HCl	Phase 3	Kidney Disease	-
Olpasiran	Phase 3	Cardiovascular Disease	-
HPN-100	Phase 3	Cirrhosis	-
AMG 386	Phase 3	Ovarian Cancer	-
Cetuximab	Phase 3	Metastatic Colorectal Cancer	-
Dexamethasone	Phase 3	Relapsed and Refractory Multiple Myeloma	-
Low-intensity chemotherapy regimen	Phase 3	Newly Diagnosed Philadelphia (Ph)-Negative B-cell Precursor Acute Lymphoblastic Leukemia (ALL)	-
Palifermin	Phase 3	Head and Neck Cancer	-
Romiplostim	Phase 3	Chemotherapy-induced Thrombocytopenia	-
AMG 531	Phase 3	Thrombocytopenia	-
Etoposide	Phase 3	Small-cell Lung Cancer	-
Cysteamine Bitartrate Delayed-release Capsules	Phase 3	Cystinosis	-
Bemarituzumab	Phase 3	Gastric Cancer	-
Etanercept	Phase 3	Rheumatoid Arthritis	-
alendronate	Phase 3	Osteoporosis	-
Erenumab	Phase 3	Migraine	-
ABP 206	Phase 3	Melanoma	-
Maridebart cafraglutide	Phase 3	Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight	-
Tarlatamab	Phase 3	Small Cell Lung Cancer	OrphanFast TrackBreakthrough
Aeroquin	Phase 3	Cystic Fibrosis	-
Commercial Formulation Etanercept	Phase 3	Arthritis, Rheumatoid; Arthritis, Psoriatic	-
ABP 959	Phase 3	Paroxysmal Nocturnal Hemoglobinuria	-
Apremilast	Phase 3	Behçet's Disease	-
Etelcalcetide	Phase 3	Secondary Hyperparathyroidism	-
Daratumumab	Phase 3	Relapsed Multiple Myeloma	-
Panitumumab	Phase 3	Metastatic Colorectal Cancer	-
Darbepoetin alfa and Epoetin alfa	Phase 3	Anemia	-
Methotrexate	Phase 3	Psoriatic Arthritis	-
Cinacalcet	Phase 3	End Stage Renal Disease	-
Evolocumab Pre-filled Syringe	Phase 3	Primary Hypercholesterolemia	-
Cystagon® (Cysteamine Bitartrate)	Phase 3	Cystinosis	-
Romozosumab	Phase 3	Postmenopausal Osteoporosis	-
Carfilzomib	Phase 3	Multiple Myeloma	-
Apremilast tablet 20 mg	Phase 3	Ankylosing Spondyloarthritis	-
Evolocumab	Phase 3	Hyperlipidemia	-
Buphenyl (NaPBA)	Phase 3	Urea Cycle Disorders	-
Paclitaxel	Phase 3	Locally Recurrent and Metastatic Breast Cancer	-
darbepoetin alfa SF	Phase 3	Kidney Disease	-
Etanercept Liquid	Phase 3	Rheumatoid Arthritis	-
FOLFIRI Regimen	Phase 3	Metastatic Colorectal Cancer	-
MR prednisone	Phase 3	Rheumatoid Arthritis	-
HZT-501	Phase 3	Osteoarthritis	-
50 mg Etanercept	Phase 3	Rheumatoid Arthritis	-
Epoetin alfa DT	Phase 3	Chronic Kidney Disease	-
Avacopan	Phase 3	Vasculitis	-
Lurbinectedin	Phase 3	Small Cell Lung Cancer (SCLC)	-
Romosozumab	Phase 3	Postmenopausal Women With Osteoporosis	-
ABP 798	Phase 3	Arthritis, Rheumatoid	-
Bortezomib	Phase 3	Multiple Myeloma	-
Abiraterone	Phase 3	Metastatic Castration-resistant Prostate Cancer	-
AMG 102	Phase 2	Cancer	-
CC10004	Phase 2	Psoriasis	-
Adecatumumab	Phase 2	Liver Metastases	-
AMG 531 (Romiplostim)	Phase 2	MDS	-
IV Bisphosphonates	Phase 2	Breast Cancer	-
Darbepoetin alfa SC	Phase 2	Anemia	-
pegfilgrastim 12 mg	Phase 2	Lymphoma	-
Sunitinib	Phase 2	Advanced Renal Cell Carcinoma	-
Panitumumab (ABX-EGF)	Phase 2	Advanced Renal Cell Carcinoma	-
AMG 853	Phase 2	Asthma	-
epratuzumab	Phase 2	Non-Hodgkin's Lymphoma	-
cinacalcet (AMG 073)	Phase 2	Secondary Hyperparathyroidism	-
VIB7734	Phase 2	Lupus Erythematosus, Systemic	-
Modified FOLFOX6	Phase 2	Advanced Solid Tumors	-
AMG 827	Phase 2	Asthma	-
IV Bisphosphonate q 4 weeks	Phase 2	Bone Metastases in Men With Hormone-Refractory Prostate Cancer	-
Pegsunercept (PEG sTNF-RI)	Phase 2	Rheumatoid Arthritis	-
MP-376	Phase 2	Cystic Fibrosis (CF)	-
Teriparatide	Phase 2	Low Bone Mineral Density	-
CCX140-B	Phase 2	Diabetic Nephropathy	-
AMG 102 at 10 mg/kg	Phase 2	Advanced Renal Cell Carcinoma	-
AMG 655	Phase 2	Metastatic Colorectal Cancer	-
BUPHENYL®	Phase 2	Urea Cycle Disorders	-
CCX-354-C	Phase 2	Rheumatoid Arthritis	-
100 mg AMG 162	Phase 2	Osteoporosis	-
filgrastim	Phase 2	Sarcoma	-
ABX-EGF	Phase 2	Non-small Cell Lung Cancer	-
VIB4920	Phase 2	Sjögren's Syndrome	-
Belatacept	Phase 2	Allografts	-
Conatumumab	Phase 2	Colon Cancer	-
cyclophosphamide	Phase 2	Breast Cancer	-
AMG 714	Phase 2	Psoriasis	-
AMG 719	Phase 2	Rheumatoid Arthritis	-
AMG 732	Phase 2	Thyroid Eye Disease	-
Abrilumab	Phase 2	Ulcerative Colitis	-
Brodalumab	Phase 2	Rheumatoid Arthritis	-
Novel Erythropoiesis Stimulating Protein (NESP) (darbepoetin alfa)	Phase 2	Anemia	-
Tezepelumab Dose 1	Phase 2	Chronic Spontaneous Urticaria	-
Recombinant Human Erythropoietin	Phase 2	Breast Cancer	-
Irinotecan	Phase 2	Metastatic Colorectal Cancer	-
CCX168	Phase 2	Vasculitis	-
ABX-EGF (panitumumab)	Phase 2	Metastatic Colorectal Cancer	-
IDE397	Phase 2	MTAP-null Non-Small-Cell Lung Cancer	-
recombinant human erythropoietin (rHuEPO)	Phase 2	Gynecological Malignancies	-
AMG 951 (rhApo2L/TRAIL)	Phase 2	Non-Small Cell Lung Cancer	-
HZN-1116	Phase 2	Sjogren's Syndrome	-
Gemcitabine	Phase 2	Lung Cancer	-
Cisplatin	Phase 2	Squamous Cell Carcinoma of Head and Neck	-
pioglitazone	Phase 2	Type 2 Diabetes Mellitus	-
Talimogene laherparepvec	Phase 2	Melanoma	-
AMG 193	Phase 2	MTAP-deleted NSCLC	-
Systemic AMG 108	Phase 2	Osteoarthritis	-
Blinatumomab (MT103)	Phase 2	Acute Lymphoblastic Leukemia	-
anakinra	Phase 2	Rheumatoid Arthritis	-
Liatermin	Phase 2	Parkinson's Disease	-
Daxdilimab	Phase 2	Alopecia Areata	-
AMG 151	Phase 2	Diabetes Mellitus	-
Intra-articular metHuIL-1ra (anakinra)	Phase 2	Osteoarthritis	-
Docetaxel	Phase 2	Advanced MTAP-null Solid Tumors	-
IV iron dextran	Phase 2	Anemia	-
Pemetrexed	Phase 2	Non Small Cell Lung Cancer	-
Neulasta	Phase 2	Breast Cancer	-
Erenumab PFS	Phase 2	Migraine	-
AMG 102 at 20 mg/kg	Phase 2	Advanced Malignant Glioma	-
CCX 354-C	Phase 2	Rheumatoid Arthritis	-
AMG 706	Phase 2	Gastrointestinal Cancer	-
AMG 386 10mg/kg	Phase 2	Gastrointestinal Cancer	-
Naproxen	Phase 2	Bone Pain in Stage I - III Breast Cancer	-
CC-10004	Phase 2	Psoriasis	-
Oprozomib	Phase 2	Multiple Myeloma	-
Previous denosumab	Phase 2	Low Bone Mass	-
AMG 108	Phase 2	Rheumatoid Arthritis	-
Sorafenib	Phase 2	Advanced Hepatocellular Carcinoma	-
Lodotra	Phase 2	Asthma	-
CCX282-B	Phase 2	Crohn's Disease	-
AMG 223	Phase 2	End Stage Renal Disease	-
Motesanib diphosphate	Phase 2	Lung Cancer	-
Rozibafusp Alfa	Phase 2	Systemic Lupus Erythematosus (SLE)	-
AMG 509	Phase 1	Prostate Cancer	Fast Track

Amgen Inc.

Market Overview

sotorasib Phase 2 Results Expected

HZN-1116 Phase 2 Results Expected

AMG 193 Phase 2 Results Expected

IDE397 Phase 2 Results Expected

Romiplostim Phase 3 Results Expected

Dazodalibep Phase 3 Results Expected

Pembrolizumab Phase 3 Results Expected

Sotorasib Phase 3 Results Expected

Docetaxel Phase 2 Results Expected

AMG 193 Phase 2 Results Expected

Dazodalibep Phase 3 Results Expected

Rocatinlimab Phase 2 Results Expected

Dazodalibep Phase 3 Results Expected

Rocatinlimab Phase 3 Results Expected

ABP 234 Phase 3 Results Expected

Tarlatamab Phase 2 Results Expected

Ocrelizumab (US) Phase 3 Results Expected

Maridebart cafraglutide Phase 3 Results Expected

AI Predictions & Institutional Flow

FDA Submissions

Drug Pipeline

Regulatory & News